Correction

Correction: Which Risk Model to Use? Clinical Implications of the ACS MRI Screening Guidelines

In this article (Cancer Epidemiol Biomarkers Prev 2013;22:146–9), which was published in the January 2013 issue of *Cancer Epidemiology, Biomarkers & Prevention* (1), the development study for the Tyrer-Cuzick model was incorrectly identified as the Mayo Clinic Benign Breast Disease cohort in the Introduction. The model is correctly identified below. The authors regret the error.

The model is a statistical model based in part on the data obtained from the International Breast Intervention Study (IBIS).

Reference

1. Ozanne EM, Drohan B, Bosinoff P, Semine A, Jellinek M, Cronin C, et al. Which risk model to use? Clinical implications of the ACS MRI screening guidelines. Cancer Epidemiol Biomarkers Prev 2013;22:146–9.

American Association for *Cancer Research*

Cancer Epidemiology, Biomarkers & Prevention

AAC R American Association for Cancer Research

Correction: Which Risk Model to Use? Clinical Implications of the ACS MRI Screening Guidelines

Updated version	Access the most recent version of this article at: doi:10.1158/1055-9965.EPI-13-0300

Cited articles	This article cites 1 articles, 1 of which you can access for free at: http://cebp.aacrjournals.org/content/22/6/1167.full#ref-list-1

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://cebp.aacrjournals.org/content/22/6/1167. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.